Literature DB >> 29111087

Angiogenic factor screening in women with mild preeclampsia - New and significant proteins in plasma.

Karol Charkiewicz1, Elwira Jasinska2, Joanna Goscik3, Ewa Koc-Zorawska4, Marcin Zorawski5, Pawel Kuc2, Grzegorz Raba6, Tomasz Kluz7, Jaroslaw Kalinka8, Agata Sakowicz9, Piotr Laudanski10.   

Abstract

INTRODUCTION: The aim of this study was to analyse a panel of 60 angiogenic factors (pro-angiogenic and antiangiogenic) in the plasma of women with mild preeclampsia.
MATERIALS AND METHODS: We recruited 21 women between 25 and 40 weeks gestation with diagnosed mild preeclampsia into the study group and 27 healthy women with uncomplicated pregnancies of corresponding gestational age to that of the study to the control group. We used a quantitative protein macroarray method that allowed for analysis of 60 angiogenic proteins per sample simultaneously.
RESULTS: We showed a statistically significant increase in the concentration of 8 proteins, interferon gamma (IFN-γ), interleukin 6 (IL-6), leukaemia inhibitory factor (LIF), heparin-binding EGF-like growth factor (HB-EGF), hepatocyte growth factor (HGF), C-X-C motif chemokine 10 (IP-10), leptin and platelet-derived growth factor BB (PDGF-BB), as well as a significant decrease in the concentration of 3 proteins, vascular endothelial growth factor (VEGF), placental growth factor (PlGF) and follistatin, in the plasma of women with preeclampsia.
CONCLUSION: Based on our findings, it seems that protein factors may play an important role in the pathogenesis of preeclampsia, and there are many proteins that have not been studied in PE to date. There are no previous studies assessing the LIF, follistatin, HGF, HB-EGF and PDGF-BB concentrations in the plasma of women with PE; therefore, our obtained results indicate that these proteins are new factors that can play an important role in the pathomechanisms of PE.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Keywords:  Angiogenesis; Angiogenic factors; Apoptosis; Cytokine; Placenta; Preeclampsia; Protein array

Mesh:

Substances:

Year:  2017        PMID: 29111087     DOI: 10.1016/j.cyto.2017.10.020

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  7 in total

Review 1.  Peripartum Cardiomyopathy and Preeclampsia: Overlapping Diseases of Pregnancy.

Authors:  Pavan Parikh; Lori Blauwet
Journal:  Curr Hypertens Rep       Date:  2018-07-03       Impact factor: 5.369

2.  Renal functional, transcriptome, and methylome adaptations in pregnant Sprague Dawley and Brown Norway rats.

Authors:  Zhong Chen; Charles Wang; Arlin Blood; Shannon Bragg; Eugenia Mata-Greenwood
Journal:  PLoS One       Date:  2022-06-16       Impact factor: 3.752

3.  Preeclamptic Women Have Decreased Circulating IL-10 (Interleukin-10) Values at the Time of Preeclampsia Diagnosis: Systematic Review and Meta-Analysis.

Authors:  Meryl C Nath; Hajrunisa Cubro; Daniel J McCormick; Natasa M Milic; Vesna D Garovic
Journal:  Hypertension       Date:  2020-10-26       Impact factor: 10.190

4.  Impact of hyperleptinemia during placental ischemia-induced hypertension in pregnant rats.

Authors:  Ana C Palei; Hunter L Martin; Barbara A Wilson; Christopher D Anderson; Joey P Granger; Frank T Spradley
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-03-12       Impact factor: 4.733

5.  Effect of Combined Spinal-Epidural Anesthesia and Total Intravenous Anesthesia on Hemodynamics and Pregnancy Outcomes of Severe Preeclampsia Pregnant Patients Undergoing Cesarean Section.

Authors:  Guangrong Wang; Pengyu Zhang; Minghui Li; Xiujuan Wu; Hua Li
Journal:  Evid Based Complement Alternat Med       Date:  2022-02-22       Impact factor: 2.629

Review 6.  The Relationship Between Peripartum Cardiomyopathy and Preeclampsia - Pathogenesis, Diagnosis and Management.

Authors:  Aleksandra Kuć; Daria Kubik; Klaudia Kościelecka; Wojciech Szymanek; Tomasz Męcik-Kronenberg
Journal:  J Multidiscip Healthc       Date:  2022-04-23

7.  Maternal plasma angiogenic and inflammatory factor profiling in foetal Down syndrome.

Authors:  Monika Zbucka-Kretowska; Karol Charkiewicz; Joanna Goscik; Slawomir Wolczynski; Piotr Laudanski
Journal:  PLoS One       Date:  2017-12-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.